Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Ibrutinib treatment before apheresis improves CAR-T therapy results in R/R DLBCL patients

Julio Chavez • 25 Nov 2020
ASH 2020
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Ibrutinib Tisagenlecleucel

Julio Chavez, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the initial results of a Phase Ib study aiming to evaluate the efficacy of ibrutinib treatment prior to and after apheresis in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients undergoing tisagenlecleucel (tisa-cel) therapy. The findings suggested that prior treatment with ibrutinib has a tolerable safety profile and may lead to an improvement in CAR-T cell quality and concentration in R/R DLCBL patients treated with tisa-cel. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Julio Chavez

3:46
ZUMA-5 update: retreatment of R/R iNHL with axi-cel
Julio Chavez • 25 Nov 2020
4:13
MEDI-570: a novel antibody therapy in R/R T-cell lymphoma
Julio Chavez • 25 Nov 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals